论文部分内容阅读
目的观察重组人干扰素α-2b雾化吸入辅助治疗毛细支气管炎的临床疗效。方法选择深圳市妇幼保健院治疗的毛细支气管炎患儿84例,随机分为2组。观察组43例,其中男性23例,女性20例,年龄(5.9±3.5)个月;对照组41例,其中男性22例,女性19例,年龄(6.2±3.8)个月。对照组采用常规治疗,并予布地奈德雾化治疗;观察组在对照组治疗基础上加用重组人干扰素α-2b空气压缩雾化吸入。用药剂量为每次50 k IU/kg,每天2次,每天最大剂量不超过1 000 k IU,疗程共5~7 d。结果观察组总有效率100.0%,对照组97.6%;两组比较,差异无统计学意义(P>0.05)。观察组治愈率93.0%,显著高于对照组(75.6%)(P<0.05)。观察组喘憋、咳喘症状及喘鸣音消失时间及住院时间等方面均较对照组明显缩短(P<0.05)。两组均未见明显不良反应。结论干扰素α-2b雾化吸入辅助治疗毛细支气管炎疗效显著,安全性好,值得推广。
Objective To observe the clinical efficacy of recombinant human interferon α-2b inhalation in the treatment of bronchiolitis. Methods Eighty-four children with bronchiolitis who were treated in Shenzhen MCH hospital were randomly divided into two groups. There were 43 males and 23 females, with a mean age of 5.9 ± 3.5 months. The control group consisted of 41 males and 22 females, with a mean age of 6.2 ± 3.8 months. The control group was treated with conventional therapy and budesonide atomization treatment; the observation group was treated with inhalation of recombinant human interferon α-2b by air compression on the basis of the control group. The dosage is 50k IU / kg each time, twice a day, the maximum daily dose does not exceed 1 000k IU, a total of 5 ~ 7d. Results The total effective rate was 100.0% in the observation group and 97.6% in the control group. There was no significant difference between the two groups (P> 0.05). The cure rate of the observation group was 93.0%, which was significantly higher than that of the control group (75.6%) (P <0.05). Observation group wheezing, cough and wheezing symptoms and disappearance of time and hospital stay were significantly shorter than the control group (P <0.05). No obvious adverse reactions were found in both groups. Conclusion IFN-α-2b nebulization assisted treatment of bronchiolitis significant effect, safety, and worth promoting.